Logo image of SLS

SELLAS LIFE SCIENCES GROUP I (SLS) Stock Fundamental Analysis

NASDAQ:SLS - Nasdaq - US81642T2096 - Common Stock - Currency: USD

1.55  0 (0%)

After market: 1.56 +0.01 (+0.65%)

Fundamental Rating

2

Overall SLS gets a fundamental rating of 2 out of 10. We evaluated SLS against 550 industry peers in the Biotechnology industry. The financial health of SLS is average, but there are quite some concerns on its profitability. SLS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SLS had negative earnings in the past year.
In the past year SLS has reported a negative cash flow from operations.
SLS had negative earnings in each of the past 5 years.
SLS had a negative operating cash flow in each of the past 5 years.
SLS Yearly Net Income VS EBIT VS OCF VS FCFSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -77.61%, SLS is not doing good in the industry: 68.73% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -97.73%, SLS is in line with its industry, outperforming 46.18% of the companies in the same industry.
Industry RankSector Rank
ROA -77.61%
ROE -97.73%
ROIC N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLS Yearly ROA, ROE, ROICSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

SLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLS Yearly Profit, Operating, Gross MarginsSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for SLS has been increased compared to 1 year ago.
The number of shares outstanding for SLS has been increased compared to 5 years ago.
SLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLS Yearly Shares OutstandingSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SLS Yearly Total Debt VS Total AssetsSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 0.95, we must say that SLS is in the distress zone and has some risk of bankruptcy.
SLS has a better Altman-Z score (0.95) than 65.27% of its industry peers.
There is no outstanding debt for SLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACCN/A
WACCN/A
SLS Yearly LT Debt VS Equity VS FCFSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

A Current Ratio of 4.64 indicates that SLS has no problem at all paying its short term obligations.
SLS has a Current ratio (4.64) which is comparable to the rest of the industry.
SLS has a Quick Ratio of 4.64. This indicates that SLS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.64, SLS perfoms like the industry average, outperforming 52.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.64
SLS Yearly Current Assets VS Current LiabilitesSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

SLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.22%, which is quite impressive.
EPS 1Y (TTM)65.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLS will show a very strong growth in Earnings Per Share. The EPS will grow by 39.91% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.12%
EPS Next 2Y10.01%
EPS Next 3Y20.15%
EPS Next 5Y39.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLS Yearly Revenue VS EstimatesSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2020 2021 2022 2023 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
SLS Yearly EPS VS EstimatesSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -2K -4K -6K -8K -10K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLS Price Earnings VS Forward Price EarningsSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLS Per share dataSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

SLS's earnings are expected to grow with 20.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.01%
EPS Next 3Y20.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SELLAS LIFE SCIENCES GROUP I

NASDAQ:SLS (8/14/2025, 7:03:36 PM)

After market: 1.56 +0.01 (+0.65%)

1.55

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11
Inst Owners14.85%
Inst Owner Change15.11%
Ins Owners0.26%
Ins Owner Change2.26%
Market Cap154.66M
Analysts82.86
Price Target6.97 (349.68%)
Short Float %27.89%
Short Ratio8.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.1%
Min EPS beat(2)26.2%
Max EPS beat(2)33.99%
EPS beat(4)4
Avg EPS beat(4)26.51%
Min EPS beat(4)21.99%
Max EPS beat(4)33.99%
EPS beat(8)5
Avg EPS beat(8)-1250.05%
EPS beat(12)6
Avg EPS beat(12)-841.34%
EPS beat(16)7
Avg EPS beat(16)-641.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.14%
PT rev (3m)17.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.67%
EPS NY rev (1m)0%
EPS NY rev (3m)18.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.57
P/tB 5.98
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS0.28
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.61%
ROE -97.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.64
Altman-Z 0.95
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y33.12%
EPS Next 2Y10.01%
EPS Next 3Y20.15%
EPS Next 5Y39.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.26%
OCF growth 3YN/A
OCF growth 5YN/A